Trends in Cancer

Article	Citations
Turning Cold into Hot: Firing up the Tumor Microenvironment	543
Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance	382
Senescent Cells in Cancer Therapy: Friends or Foes?	242
Glioblastoma Stem Cells: Driving Resilience through Chaos	210
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions	208
Exosomes as a Multicomponent Biomarker Platform in Cancer	172
Clinical Development of BRAF plus MEK Inhibitor Combinations	164
Cancer Epigenetics, Tumor Immunity, and Immunotherapy	163
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View	156
Necroptosis and tumor progression	155
Targeting Glycosylation: A New Road for Cancer Drug Discovery	145
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors	139
Gut Microbiota in Cancer Immune Response and Immunotherapy	131
RNA Splicing and Cancer	130
MGMT Status as a Clinical Biomarker in Glioblastoma	127
Promoter DNA Hypermethylation and Paradoxical Gene Activation	127
Emerging Mechanisms by which EMT Programs Control Stemness	121
Advanced Prostate Cancer: Treatment Advances and Future Directions	118
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence	96
Molecular Tumor Boards in Clinical Practice	91
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy	89
Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle	88
Extracellular Vesicles in Cancer Detection: Hopes and Hypes	85
Better together: circulating tumor cell clustering in metastatic cancer	84
Tumor Plasticity and Resistance to Immunotherapy	83

Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy	82
Precision therapy for RET-altered cancers with RET inhibitors	82
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy	81
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?	80
Targeting ferroptosis in pancreatic cancer: a double-edged sword	75
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance	74
Tunneling Nanotubes: The Fuel of Tumor Progression?	72
Mitochondrial Stress Response and Cancer	69
Revisiting the HIF switch in the tumor and its immune microenvironment	66
Tweak to Treat: Reprograming Bacteria for Cancer Treatment	66
TRAIL of Hope Meeting Resistance in Cancer	66
Zebrafish Xenografts for Drug Discovery and Personalized Medicine	65
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	63
Targeting CAFs to overcome anticancer therapeutic resistance	63
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm	59
Targeting SUMO Signaling to Wrestle Cancer	58
FTO in cancer: functions, molecular mechanisms, and therapeutic implications	56
Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases	55
Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma	54
Pharmacological Targeting of IRE1 in Cancer	54
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids	53
Inflammation: the incubator of the tumor microenvironment	53
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	53
Challenges in glioblastoma research: focus on the tumor microenvironment	51
Targeting the Mevalonate Pathway in Cancer	49
Utilizing chemokines in cancer immunotherapy	49
C1q+ macrophages: passengers or drivers of cancer progression	49
Drug independence and the curability of cancer by combination chemotherapy	48
The Role of the Microenvironment and Immune System in Regulating Stem Cell Fate in Cancer	48
Nanotherapeutics for Antimetastatic Treatment	47
NF-κB in the New Era of Cancer Therapy	47
Targeting the replication stress response through synthetic lethal strategies in cancer medicine	46
Radiotherapy and immunotherapy: open questions and future strategies	45
Mutagenesis by Microbe: the Role of the Microbiota in Shaping the Cancer Genome	45
Therapeutic targeting of regulatory T cells in cancer	45
Coagulome and the tumor microenvironment: an actionable interplay	44
Liver Inflammation and Hepatobiliary Cancers	44
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy	43
Antibody–drug conjugates: in search of partners of choice	43
Roles and Regulations of TET Enzymes in Solid Tumors	43
Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity	42
The emerging field of oncolytic virus-based cancer immunotherapy	42
Alternative Lengthening of Telomeres: Building Bridges To Connect Chromosome Ends	42
Tumor Innervation: Cancer Has Some Nerve	41
Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers	41
Reconciling Non-Genetic Plasticity with Somatic Evolution in Cancer	41
Emerging Players in Prostate Cancer–Bone Niche Communication	40
Evolution of metastasis: new tools and insights	39
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology	39
Cancer Plasticity: The Role of mRNA Translation	39

Towards the Microbial Production of Plant-Derived Anticancer Drugs	38
Drilling for Oil: Tumor-Surrounding Adipocytes Fueling Cancer	37
T follicular helper cells in cancer	37
The Hippo Pathway as a Driver of Select Human Cancers	37
Nanomedicine-based strategies to target and modulate the tumor microenvironment	36
The spectrum of sex differences in cancer	36
Improving Bioprinted Volumetric Tumor Microenvironments In Vitro	36
Hypertranscription and replication stress in cancer	35
Single cell cancer epigenetics	35
Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer	35
Life and Death Decision-Making by p53 and Implications for Cancer Immunotherapy	35
How cancer cells make and respond to interferon-I	34
Cancer of Unknown Primary in the Molecular Era	34
Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation	33
RAC1 as a Therapeutic Target in Malignant Melanoma	33
HLA-G/LILRBs: A Cancer Immunotherapy Challenge	33
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	32
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy	32
Technical and biological constraints on ctDNA-based genotyping	32
Tele-oncology in the COVID-19 Era: The Way Forward?	31
Why Great Mitotic Inhibitors Make Poor Cancer Drugs	31
Bispecific Antibodies for Triple Negative Breast Cancer	31
Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides	31
Tumour microenvironment 3D-modelling: simplicity to complexity and back again	31
Therapeutic Repurposing of Biguanides in Cancer	30
PML Nuclear Body Biogenesis, Carcinogenesis, and Targeted Therapy	30
Regulation of extrinsic apoptotic signaling by c-FLIP: towards targeting cancer networks	30
Understanding the Cause and Consequence of Tumor Heterogeneity	30
Cell death, therapeutics, and the immune response in cancer	29
Tissue architecture in tumor initiation and progression	29
Mitochondrial DNA is a major source of driver mutations in cancer	28
Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment	28
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity	27
Pediatric Cancer Models in Zebrafish	27
The Dual Role of High Endothelial Venules in Cancer Progression versus Immunity	27
Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms	27
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	27
Microfluidics meets 3D cancer cell migration	26
DNA Damage Repair Deficiency in Prostate Cancer	25
Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis	25
How Comorbidities Shape Cancer Biology and Survival	25
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer	25
Genes that Mediate Metastasis across the Blood–Brain Barrier	24
Beyond Kinases: Targeting Replication Stress Proteins in Cancer Therapy	24
Human-Derived Model Systems in Gynecological Cancer Research	24
Building Diverse Mentoring Networks that Transcend Boundaries in Cancer Research	24
Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer	24
Chromosomal instability and aneuploidy as causes of cancer drug resistance	24
Tackling PARP inhibitor resistance	23
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	23
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma	23
Age-associated differences in the cancer molecular landscape	23
New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?	23
T cell exhaustion in malignant gliomas	23
Immunity beyond cancer cells: perspective from tumor tissue	22
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	22
The Mystery of Rap1 Suppression of Oncogenic Ras	22
Synthetic Lethal Interactions of RECQ Helicases	22
Exploiting cancer’s drinking problem: regulation and therapeutic potential of macropinocytosis	22
Engineering stem cells for cancer immunotherapy	22
Cancer cell adaptability: turning ribonucleoprotein granules into targets	22
Group Behavior and Emergence of Cancer Drug Resistance	21
Cellular and molecular mechanisms of plasticity in cancer	21
Mice Are Not Humans: The Case of p53	21
Role of financial toxicity in perpetuating health disparities	21
Emerging mechanisms of telomerase reactivation in cancer	21
SPAG5: An Emerging Oncogene	21
Neuronal and tumourigenic boundaries of glioblastoma plasticity	20
Artificial intelligence-guided discovery of anticancer lead compounds from plants and associated microorganisms	20
Tumor Excision as a Metastatic Russian Roulette: Perioperative Interventions to Improve Long-Term Survival of Cancer Patients	20
GSDME: A Potential Ally in Cancer Detection and Treatment	20
Lipid in Renal Carcinoma: Queen Bee to Target?	20
The Anticancer Potential of T Cell Receptor-Engineered T Cells	20
Emerging metabolomic tools to study cancer metastasis	20
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	19
Epigenetic basis and targeting of cancer metastasis	19
Computing the Role of Alternative Splicing in Cancer	19
DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer	19
Aneuploidy in Cancer: Lessons from Acute Lymphoblastic Leukemia	19
Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All	19

Immune response and inflammation in cancer health disparities	18
Genomic Instability in Multiple Myeloma	18
Leveraging Single-Cell Approaches in Cancer Precision Medicine	18
Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities	18
Ecology and evolution of dormant metastasis	17
Immune mechanisms of toxicity from checkpoint inhibitors	17
Capicua in Human Cancer	17
Mechanisms of PDAC subtype heterogeneity and therapy response	17
Implications of Tumor–Immune Coevolution on Cancer Evasion and Optimized Immunotherapy	17
Pannexin biology and emerging linkages to cancer	17
Managing Cancer Care during the COVID-19 Pandemic and Beyond	17
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises	17
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	17
Radiotherapy-induced metabolic hallmarks in the tumor microenvironment	17
A specialist-generalist framework for epithelial-mesenchymal plasticity in cancer	16
Fluorescence Sheds Light on DNA Damage, DNA Repair, and Mutations	16
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	16
CHEK2 variants: linking functional impact to cancer risk	16
T cell-mediated additive cytotoxicity – death by multiple bullets	15
Immune organoids: from tumor modeling to precision oncology	15
Tumor immunology CRISPR screening: present, past, and future	15
Cell Competition Spurs Selection of Aggressive Cancer Cells	15
Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas	15
Tumor mutational burden and immunotherapy in gliomas	15
Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity	14
Mitochondrial DNA Haplotypes as Genetic Modifiers of Cancer	14
Novel Forms of Immunomodulation for Cancer Therapy	14
Fanconi anemia proteins and genome fragility: unraveling replication defects for cancer therapy	14
Targeting TGFβ Signalling in Cancer: Toward Context-Specific Strategies	14
Modeling metastasis in mice: a closer look	13
The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer	13
Drivers of Gene Expression Dysregulation in Pancreatic Cancer	13
Exploiting T cell signaling to optimize engineered T cell therapies	13
Antimetastatic defense by CD8+ T cells	13
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents	13
Optical Microscopy and Coherence Tomography of Cancer in Living Subjects	13
On a New Proposed Mechanism of 5-Fluorouracil-Mediated Cytotoxicity	13
Cancer catecholamine conundrum	13
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance	13
PALB2 Variants: Protein Domains and Cancer Susceptibility	12
Illuminating Non-genetic Cellular Heterogeneity with Imaging-Based Spatial Proteomics	12
From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts	12
BAG3 in Tumor Resistance to Therapy	12
Exercise Benefits Meet Cancer Immunosurveillance: Implications for Immunotherapy	12
Optimizing the future: how mathematical models inform treatment schedules for cancer	12
Concepts and Applications of Information Theory to Immuno-Oncology	12
RHOA takes the RHOad less traveled to cancer	11
Preclinical to clinical utility of ROCK inhibitors in cancer	11
Redrawing therapeutic boundaries: microbiota and cancer	11
Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma	11
Can Energetic Capacity Help Explain Why Physical Activity Reduces Cancer Risk?	11
Impact of tissue-agnostic approvals for patients with sarcoma	11
Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers	11
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy	11
Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges	11
Tilting MYC toward cancer cell death	11
Multicellular modules as clinical diagnostic and therapeutic targets	10
Understanding how genetic ancestry may influence cancer development	10
Biophysical determinants of cancer organotropism	10
Translational Control of Immune Evasion in Cancer	10
Targeting Serine in Cancer: Is Two Better Than One?	10
Fasting and fasting mimicking diets in cancer prevention and therapy	10
To Vaccinate or not: Influenza Virus and Lung Cancer Progression	10
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer	10
Shadow mentoring: a cost–benefit review for reform	10
Tele-oncology in the COVID-19 Era: Are Medical Students Left Behind?	9
Modulating Treg stability to improve cancer immunotherapy	9
Spatial determinants of CD8+ T cell differentiation in cancer	9
Intestinal stem cell dynamics in homeostasis and cancer	9
Gap Junctions and Breast Cancer Dormancy	9
Interleukin-10 in cancer immunotherapy: from bench to bedside	9
Interplay between K-RAS and miRNAs	9
Epigenetic Biomarkers in Gallbladder Cancer	9
Targeting synthetic lethal paralogs in cancer	9
Converging technologies: targeting the hallmarks of cancer using ultrasound and microbubbles	9
Tumor Functional Heterogeneity Unraveled by scRNA-seq Technologies	9
Engine shutdown: migrastatic strategies and prevention of metastases	9
Transcriptional determinants of cancer immunotherapy response and resistance	8
Insights on ErbB glycosylation – contributions to precision oncology	8
High-Fat Diet Impacts on Tumor Development in the Gut	8
Immune Checkpoint Inhibition in Prostate Cancer	8
Harnessing Real-World Evidence for the Development of Novel Cancer Therapies	8
TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities	8
Senescent stromal cells: roles in the tumor microenvironment	8
Why Tumor Genetic Heterogeneity May Require Rethinking Cancer Genesis and Treatment	8
A Quantitative Paradigm for Decision-Making in Precision Oncology	8
The unequal burden of time toxicity	7
The conundrum of Helicobacter pylori-associated apoptosis in gastric cancer	7
Endogenous retroelements as alarms for disruptions to cellular homeostasis	7
Above and Beyond Cancer Therapy: Translating Biomaterials into the Clinic	7
Brachyury: Strategies for Drugging an Intractable Cancer Therapeutic Target	7
Solving the puzzle of what makes immunotherapies work	7
Next batter up! Targeting cancers with KRAS-G12D mutations	7
Immunometabolism: A ‘Hot’ Switch for ‘Cold’ Pediatric Solid Tumors	7
Advances in targeting RNA modifications for anticancer therapy	7